Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 301.48m |
Free float | 141.84m |
P/E (TTM) | -- |
Market cap | 3.75bn USD |
EPS (TTM) | -1.90 USD |
--
More ▼
Announcements
- Alvotech birtir fjárhagsuppgjör fyrir fyrstu níu mánuði ársins 2024
- Alvotech Reports Financial Results for the First Nine Months of 2024
- Alvotech fundar með fjárfestum á heilbrigðisráðstefnum Citi og Evercore fjárfestingabankanna dagana 4. og 5. desember 2024
- Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
- European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
- Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT05, fyrirhugaða líftæknilyfjahliðstæðu við Simponi (golimumab)
- Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
- Alvotech mun birta uppgjör fyrstu níu mánaða ársins miðvikudaginn 13. nóvember nk. og streyma uppgjörsfundi fimmtudaginn 14. nóvember nk. kl. 13:00 að íslenskum tíma
- Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
- Alvotech fundar með fjárfestum og heldur kynningu á heilbrigðisráðstefnu Jefferies í London 19.-20. nóvember 2024
More ▼